4DMedical Secures One-Year Deal With GlaxoSmithKline

MT Newswires Live
04/20

4DMedical (ASX:4DX) secured a one-year contract with GlaxoSmithKline, in collaboration with imaging data platform Flywheel Exchange, to provide its quantitative lung imaging analytics from May to support pulmonary drug development and clinical research, according to a Monday filing with the Australian bourse.

Additionally, the company's CT:VQ imaging technology obtained UK Conformity Assessed certification, allowing for the commercial deployment across both public and private healthcare providers within the UK, the filing said.

The company will also be included in the S&P/ASX 200 Index, effective before the open of trading on Monday, per the filing.

4DMedical's shares rose around 1% in morning trade Monday.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10